凝血因子VIII与患者来源抗C1结构域抗体抑制剂结合的结构
约30%接受替代治疗的先天性血友病A患者及所有获得性血友病A患者会产生针对凝血因子VIII(FVIII)的致病性抗体抑制剂。本研究通过单颗粒冷冻电镜解析了FVIII与KM33重组衍生物NB33结合的結構,发现NB33表位位于C1结构域膜结合环的R2090-S2094和I2158-R2159残基,并揭示多个先前介导LRP1结合的FVIII赖氨酸和精氨酸残基对接至NB33可变域界面的酸性裂隙,从而阻断推定的LRP1结合位点。
要点
- KM33是来自重型血友病A患者的抗C1结构域抗体抑制剂,其重组衍生物NB33用于结构解析。
- NB33表位定位于FVIII C1结构域膜结合环的R2090-S2094和I2158-R2159残基。
- 多个介导LRP1结合的FVIII赖氨酸和精氨酸残基对接至NB33可变域界面酸性裂隙,阻断推定的LRP1结合位点。
核心结论
- 患者来源抗体抑制剂NB33通过阻断FVIII上推定的LRP1结合位点发挥抑制作用的机制是新颖的。
- 结构分析结果为工程化改造FVIII以降低LRP1介导的清除提供了结构证据。
研究设计与样本
- 研究采用单颗粒冷冻电镜解析FVIII与NB33(KM33的重组衍生物)结合的复合物结构。
- NB33是先前从重型血友病A患者中分离的抗C1结构域抗体抑制剂KM33的重组衍生物。
主要发现
- NB33表位定位于FVIII残基R2090-S2094和I2158-R2159,这些残基构成C1结构域的膜结合环。
- 多个先前显示介导LRP1结合的FVIII赖氨酸和精氨酸残基对接至NB33可变域界面的酸性裂隙,从而阻断推定的LRP1结合位点。
- KM33可强效阻断FVIII与冯·维勒布兰德因子和磷脂表面的结合,并破坏FVIII与LRP1的结合,后者驱动FVIII肝脏清除和树突状细胞中的抗原呈递。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of pathogenic antibody inhibitors against coagulation factor VIII (FVIII) occurs in ∼30% of patients with congenital hemophilia A receiving FVIII replacement therapy, as well as in all cases of acquired hemophilia A. KM33 is an anti-C1 domain antibody inhibitor previously isolated from a patient with severe hemophilia A. In addition to potently blocking FVIII binding to von Willebrand factor and phospholipid surfaces, KM33 disrupts FVIII binding to lipoprotein receptor-related protein 1 (LRP1), which drives FVIII hepatic clearance and antigen presentation in dendritic cells. Here, we report on the structure of FVIII bound to NB33, a recombinant derivative of KM33, via single-particle cryo-electron microscopy. Structural analysis revealed that the NB33 epitope localizes to the FVIII residues R2090-S2094 and I2158-R2159, which constitute membrane-binding loops in the C1 domain. Further analysis revealed that multiple FVIII lysine and arginine residues, previously shown to mediate binding to LRP1, dock onto an acidic cleft at the NB33 variable domain interface, thus blocking a putative LRP1 binding site. Together, these results demonstrate a novel mechanism of FVIII inhibition by a patient-derived antibody inhibitor and provide structural evidence for engineering FVIII with reduced LRP1-mediated clearance.
引用
- Childers KC, Avery NG, Estrada Alamo KA, et al. Structure of coagulation factor VIII bound to a patient-derived anti-C1 domain antibody inhibitor. Blood. 2023. PMID: 37192299. doi:10.1182/blood.2023020181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。